Bulletin
Investor Alert

New York Markets After Hours

Dec. 30, 2020, 6:47 a.m. EST

U.K. approves coronavirus vaccine AstraZeneca made with Oxford

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AstraZeneca PLC ADR (AZN)
  • X
    AstraZeneca PLC (AZN)
  • X
    Pfizer Inc. (PFE)

or Cancel Already have a watchlist? Log In

By Steve Goldstein

AstraZeneca on Wednesday said the coronavirus vaccine it has developed with the University of Oxford has been approved by the U.K. government.

AstraZeneca /zigman2/quotes/200304487/composite AZN +0.09% /zigman2/quotes/203048482/delayed UK:AZN +0.46% said the COVID-19 vaccine has been approved for emergency supply in the U.K. so that vaccinations may begin early in the new year.

London-listed pharmaceutical company AstraZeneca’s shares edged higher, but the stock has slipped 11% over the last three months.

It said the U.K.’s Medicines and Healthcare products Regulatory Agency has provided authorization for emergency supply of what it now calls COVID-19 Vaccine AstraZeneca.

The authorization recommends two doses administered with an interval of between four and 12 weeks.

The U.K. was the first government to approve the vaccine made by U.S. drug company Pfizer /zigman2/quotes/202877789/composite PFE +1.77% and its German partner BioNTech /zigman2/quotes/214419716/composite BNTX -4.91% , and has administered the third-highest total of shots, according to the Our World in Data tracker.

The AstraZeneca vaccine was criticized after data showed it was more effective with a half dose followed by a full dose, rather than two full doses. AstraZeneca said additional safety and efficacy data for the vaccine will continue to accumulate from ongoing clinical trials.

At a press conference, regulators cited the overall 70% effectiveness rate the AstraZeneca vaccine achieved in both of its dosing studies. They also advised against mixing-and-matching the AstraZeneca and Pfizer vaccines.

The advantage the AstraZeneca vaccine has over the Pfizer one is that it can be stored at normal refrigeration temperatures, rather than needing supercold storage. AstraZeneca plans to make up to 3 billion vaccines to be distributed throughout the developing world.

The U.K. government said the approval will allow for the country’s entire population to be vaccinated. The U.K. has been effectively isolated from the rest of the world, as a new strain has rapidly spread.

/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 54.88
+0.05 +0.09%
Volume: 4.90M
Dec. 1, 2021 4:00p
P/E Ratio
86.62
Dividend Yield
2.50%
Market Cap
$169.62 billion
Rev. per Employee
$362,602
loading...
/zigman2/quotes/203048482/delayed
UK : U.K.: London
8,314.00 p
+38.00 +0.46%
Volume: 1.87M
Dec. 1, 2021 4:35p
P/E Ratio
88.55
Dividend Yield
2.43%
Market Cap
£128.21 billion
Rev. per Employee
£282,763
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 54.68
+0.95 +1.77%
Volume: 58.93M
Dec. 1, 2021 4:03p
P/E Ratio
16.23
Dividend Yield
2.85%
Market Cap
$301.58 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 334.48
-17.26 -4.91%
Volume: 3.71M
Dec. 1, 2021 4:00p
P/E Ratio
9.66
Dividend Yield
N/A
Market Cap
$85.30 billion
Rev. per Employee
$283,276
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.